Health & Education · Warsaw
Obesity drug makers lobby for reimbursement that could cost Poland 1.4-1.5 bn zloty
Eli Lilly and Novo Nordisk paid about 25 million zloty to doctors and health groups in 2025, while Poles spent almost 1.5 billion zloty on Mounjaro and Wegovy out of their own pockets.
AI text based on reports by rmf24.pl and Rzeczpospolita. Published . How it is made
For membersThe first 30 seconds for everyone. Synthetic voice (AI).
In brief
Eli Lilly and Novo Nordisk paid about 25 million zloty in 2025, with 16 million zloty for sponsorship and 9 million zloty for medical services.
Estimates put the extra cost of reimbursing Mounjaro at about 550 million zloty over two years and Wegovy at about 860 million zloty over four years, and the AOTMiT has not yet recommended either drug.
In 2025 Poles spent 1.292 billion zloty on Mounjaro and 182 million zloty on Wegovy, a total above 2 billion zloty once Ozempic and Rybelsus are included.
Payments to the medical sector
Eli Lilly and Novo Nordisk, which make the obesity drugs Mounjaro and Wegovy, paid doctors and health organisations about 25 million zloty in 2025. Of that sum, 16 million zloty went to sponsorship of scientific societies, universities, hospitals and patient organisations, and 9 million zloty covered fees for medical services. These figures leave out extra costs such as funding doctors' trips to conferences. The payments form part of a wider pattern in which manufacturers finance the people and groups that shape treatment debates.
- Sponsorship of societies, universities, hospitals and patient groups
- 16 mln zł
- Fees for medical services
- 9 mln zł
Data from the article text
Campaigns and lobbying
Campaigns and educational initiatives on treating obesity are partly financed by the manufacturers. Some of the organisations taking part in events, including ones held in parliament, are financed by the drugmakers. Monika Wielichowska, deputy Marshal of the Sejm, and senator Agnieszka Gorgoń-Komor, both from the Civic Coalition, are named as especially active in the fight against obesity. Representatives of the Ministry of Health have voiced concern that lobbying has gone beyond the walls of parliament and the limits of decency.
Reimbursement and the state budget
Applications for reimbursing the two drugs are on the table, but the president of the Agency for Health Technology Assessment and Tariff System (AOTMiT) has not yet recommended reimbursing either therapy. Estimates put the extra cost to the budget at about 550 million zloty over two years for Mounjaro and about 860 million zloty over four years for Wegovy. Rzeczpospolita puts the total cost to the state at 1.4 billion zloty over several years, while another article gives about 1.5 billion zloty over several years. The gap between the two figures is one of the open questions in the debate.
- Mounjaro (2 years)
- 550 mln zł
- Wegovy (4 years)
- 860 mln zł
Data from the article text
What patients pay now
Polish patients already spent heavily on these products in 2025 out of their own pockets. They paid 1.292 billion zloty for Mounjaro and 182 million zloty for Wegovy, almost 1.5 billion zloty in total. According to Rzeczpospolita, adding Ozempic and Rybelsus, which are used outside their approved indications, pushes the figure above 2 billion zloty. The two obesity drugs rank among the top-selling non-reimbursed prescription medicines in Poland by revenue. The data come from the latest report of the Economic Commission at the Ministry of Health.
- Mounjaro
- 1292 mln zł
- Wegovy
- 182 mln zł
Data from the article text
Who benefits
Besides the manufacturers, doctors, health experts and patient organisation representatives benefit from the treatment market. Their names and affiliations appear in transparency reports that the drugmakers publish. Rzeczpospolita describes the market for obesity drugs as worth at least 1.5 billion zloty a year. The Foundation for Obesity Treatment (FLO), set up in 2023, is among the main actors in the debate.
Ask about this text
Sources and context
- rmf24.plObesity costs billions of zloty. Drug manufacturers want money from the state budgetOtyłość kosztuje miliardy złotych. Producenci leków chcą pieniędzy z budżetu państwa · original in Polish
- RzeczpospolitaA disease worth its weight in gold. Money from drug manufacturers is behind the obesity debateChoroba na wagę złota. Za debatą na temat otyłości stoją pieniądze od producentów leków · original in Polish
- Monika Wielichowska
- Deputy Marshal of the Sejm (Civic Coalition), named as especially active in the fight against obesity
- Agnieszka Gorgoń-Komor
- Senator from the Civic Coalition, named as especially active in the fight against obesity
- Places
- Warsaw
Pollar is free and carries no ads in the text. Its members keep it going.
Support Pollar